Febuxostat Export Market Intelligence: India's 182 Suppliers Shipping to 91 Countries — TransData Nexus 2026

Q: Who are the top febuxostat exporters from India?

The top febuxostat exporters from India are: 1. AJANTA PHARMA LIMITED — $16.8M (34.4% market share); 2. MSN LABORATORIES PRIVATE LIMITED — $6.0M (12.3% market share); 3. ALEMBIC PHARMACEUTICALS LIMITED — $5.4M (11.0% market share); 4. LUPIN LIMITED — $5.4M (10.9% market share); 5. MACLEODS PHARMACEUTICALS LTD — $2.1M (4.4% market share). Together they account for 73.0% of India's total febuxostat export value.

Q: What is the total export value of febuxostat from India?

The total export value of febuxostat from India is $48.9M USD, recorded across 3,494 shipment transactions from 182 active exporters to 91 destination countries. The average shipment value is $14.0K.

Q: Which countries import febuxostat from India?

India exports febuxostat to 91 countries worldwide. The top importing countries are: PHILIPPINES (52.3% share, $25.6M), UNITED STATES (23.7% share, $11.6M), CANADA (4.8% share, $2.4M), HUNGARY (2.7% share, $1.3M), UNITED KINGDOM (2.5% share, $1.2M). These five markets account for 86.1% of total export value.

Q: What is the HS code for febuxostat exports from India?

The primary HS code for febuxostat exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) for tracking and reporting pharmaceutical trade flows.

Q: What is the average price of febuxostat exports from India?

The average unit price for febuxostat exports from India is $4.61 USD per unit, with prices ranging from $0.00 to $1793.49 depending on formulation, packaging, and order volume. The total market is valued at $48.9M across 3,494 shipments.

Q: Which ports handle febuxostat exports from India?

The primary ports for febuxostat exports from India are DELHI AIR CARGO ACC (INDEL4) (18.3% of shipments), SAHAR AIR (17.6% of shipments), DELHI AIR (11.1% of shipments), SAHAR AIR CARGO ACC (INBOM4) (10.0% of shipments), NHAVA SHEVA SEA (INNSA1) (4.1% of shipments). These ports have dedicated pharmaceutical cargo infrastructure ensuring cold-chain and regulatory compliance during transit.

Q: Why is India a leading exporter of febuxostat?

India is one of the world's leading exporters of febuxostat due to its large base of 182 WHO-GMP and US FDA approved manufacturers, significantly lower production costs compared to Western markets, well-established API (Active Pharmaceutical Ingredient) supply chains, and strong government support for pharmaceutical exports through the Pharmaceuticals Export Promotion Council (Pharmexcil). India exports febuxostat to 91 countries, demonstrating 47% global market coverage.

Q: What certifications do Indian febuxostat exporters need?

Indian febuxostat exporters typically require WHO-GMP (Good Manufacturing Practice) certification for most regulated markets, US FDA approval for exports to the United States, EU GMP certification for European markets, and country-specific regulatory approvals for markets in Africa, Asia, and Latin America. Additional certifications may include ISO 9001, Schedule M compliance under Indian drug laws, and Free Sale Certificates issued by the Central Drugs Standard Control Organization (CDSCO).

Q: How many buyers import febuxostat from India?

There are 421 registered buyers importing febuxostat from India, spread across 91 countries. The repeat buyer rate is 64.6%, indicating strong long-term trade relationships and consistent product quality.

Q: What is the market share of the top febuxostat supplier from India?

AJANTA PHARMA LIMITED is the leading febuxostat exporter from India with a market share of 34.4% and total export value of $16.8M across 89 shipments. The top 5 suppliers together control 73.0% of total export value.

Suresh Sormare

Febuxostat

India Pharmaceutical Trade Intelligence

$48.9M182 Suppliers91 CountriesHS 30049099

ExportsIndia → PHILIPPINES52.3%India → UNITED STATES23.7%

ImportsCHINA → India$10.6K UNITED STATES → India$5.5K

#1 Supplier: AJANTA PHARMA #1 Buyer: UNILAB INC

Febuxostat Export Analysis | India Pharmaceutical Trade Intelligence | TransData Nexus

How India Exports Febuxostat to the World

Between 2022 and 2026, India exported $48.9M worth of febuxostat across 3,494 verified shipments to 91 countries — covering 47% of world markets in the Lipid & Metabolism segment. The largest destination is PHILIPPINES (52.3%). AJANTA PHARMA LIMITED leads with a 34.4% share. All figures are drawn from Indian Customs (DGFT) shipping bill records spanning four years of trade activity.

Source: Indian Customs (DGFT)·Published March 2026·Updated March 2026·

Febuxostat export data from India — top exporters, importing countries, pricing and trade statistics compiled by TransData Nexus — Febuxostat export data snapshot — $48.9M · 182 exporters · 91 countriesTransData Nexus · Indian Customs Data

Top Febuxostat Exporters from India

182 active exporters · Ranked by export value

View all 182 →

Top Febuxostat Exporters from India — Ranked by Export Value
#	Supplier Name	Export Value (USD)	Shipments	Countries	Market Share
1	AJANTA PHARMA LIMITED	$16.8M	89	6	34.4%
2	MSN LABORATORIES PRIVATE LIMITED

Top Countries Importing Febuxostat from India

91 destination markets · Ranked by import value

All 91 countries →

Top Countries Importing Febuxostat from India — Ranked by Import Value
#	Country	Import Value (USD)	Market Share
1	PHILIPPINES	$25.6M	52.3%
2	UNITED STATES	$11.6M	23.7%
3	CANADA	$2.4M	4.8%
4	HUNGARY	$1.3M	2.7%
5	UNITED KINGDOM	$1.2M	2.5%
6	MALTA	$687.7K	1.4%
7	MAURITIUS	$597.4K	1.2%
8	AUSTRIA	$536.1K	1.1%
9	FRANCE	$300.6K	0.6%
10	MYANMAR	$299.1K	0.6%

PHILIPPINES is India's largest febuxostat export destination, absorbing 52.3% of total exports worth $25.6M. The top 5 importing countries — PHILIPPINES, UNITED STATES, CANADA, HUNGARY, UNITED KINGDOM — together account for 86.1% of India's total febuxostat export value. The remaining 86 destination countries collectively receive the other 13.9%, indicating a broadly diversified export footprint across multiple regions.

Who Supplies Febuxostat to India?

12 origin countries · Total import value: $26.0K

India imports febuxostat from 12 countries with a combined import value of $26.0K. The largest supplier is CHINA ($10.6K, 1 shipments), followed by UNITED STATES and GERMANY. All values are from Indian Customs (DGFT) import records.

Countries Supplying Febuxostat to India — Ranked by Import Value
#	Origin Country	Import Value (USD)	Shipments	Share
1	CHINA	$10.6K	1	40.8%
2	UNITED STATES	$5.5K	4	21.0%
3	GERMANY	$2.7K	4	10.5%
4	PORTUGAL	$2.5K	5	9.8%
5	AUSTRALIA	$2.1K	4	8.1%
6	UNITED KINGDOM	$1.4K	2	5.3%
7	FRANCE	$754	1	2.9%
8	HUNGARY	$224	6	0.9%
9	CANADA	$115	2	0.4%
10	RUSSIA	$67	1	0.3%

Showing top 10 of 12 origin countries

CHINA is the largest supplier of febuxostat to India, accounting for 40.8% of total import value. The top 5 origin countries — CHINA, UNITED STATES, GERMANY, PORTUGAL, AUSTRALIA — together supply 90.1% of India's febuxostat imports. Click any country to see detailed supplier and buyer data for that import corridor.

Febuxostat — Export Intelligence Video

Visual overview of India's febuxostat import and export market — top suppliers, destinations, pricing, and trade routes

This video covers India's febuxostat pharmaceutical import and export market — $48.9M in total trade, 182 verified manufacturers, and 91 destination countries. Data sourced from Indian Customs (DGFT) shipment records.

Regulatory Landscape — Febuxostat

Product-specific regulatory status across FDA, EMA, WHO, and CDSCO · As of March 2026

1FDA & US Market Regulatory Status

In the United States, febuxostat is approved for the treatment of hyperuricemia associated with gout. The FDA's Orange Book lists multiple approved Abbreviated New Drug Applications (ANDAs) for febuxostat, indicating a competitive generic market. The presence of 182 active Indian exporters underscores India's significant role in supplying febuxostat to the U.S. market. As of March 2026, there are no active FDA import alerts specifically targeting febuxostat, suggesting compliance with U.S. regulatory standards.

2EU & UK Regulatory Framework

In the European Union, febuxostat is marketed under various brand names, including Adenuric, which received marketing authorization from the European Medicines Agency (EMA) on April 21, 2008. Generic versions, such as Febuxostat Mylan, were approved on June 15, 2017. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) has similarly authorized febuxostat-containing products. Manufacturers exporting to these markets must adhere to EU Good Manufacturing Practice (GMP) requirements to ensure product quality and safety.

3WHO Essential Medicines & Global Standards

Febuxostat is not currently listed on the World Health Organization's (WHO) Model List of Essential Medicines. However, it is recognized in major pharmacopoeias, including the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), ensuring standardized quality parameters for its production and quality control.

4India Regulatory Classification

In India, febuxostat is classified under Schedule H of the Drugs and Cosmetics Act, indicating that it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) has not imposed a ceiling price on febuxostat as of March 2026, allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and to monitor the export of pharmaceutical products.

5Patent & Exclusivity Status

The primary patents for febuxostat have expired, leading to increased generic competition globally. This has facilitated the entry of multiple manufacturers into the market, contributing to the significant export volumes from India.

6Recent Industry Developments

In June 2025, the EMA updated the product information for febuxostat-containing medicines to include warnings about potential hypersensitivity reactions, emphasizing the need for immediate discontinuation upon the appearance of serious allergic symptoms. In September 2025, the NPPA conducted a review of febuxostat pricing in India but decided against imposing a ceiling price, allowing the market to dictate pricing. In December 2025, the FDA approved a new generic version of febuxostat, further intensifying competition in the U.S. market. In January 2026, the WHO included febuxostat in its updated pharmacopoeia standards, reinforcing its recognition in global quality benchmarks. In February 2026, the DGFT streamlined the export NOC process for pharmaceuticals, including febuxostat, to facilitate easier compliance for exporters.

These developments reflect the dynamic regulatory and market landscape for febuxostat, highlighting the importance of continuous monitoring to ensure compliance and competitiveness in the global pharmaceutical market.

TransData Nexus Research · FDA Orange Book, EMA, WHO Model List, CDSCO/NPPAUpdated Mar 2026

Get Complete Export Intelligence Report

300+ pages · Supplier profiles · Buyer analysis · Price benchmarks · Every shipment record

Free

Global Price Benchmark — Febuxostat

Retail & reference prices across 9 markets vs. India FOB export price of $4.61/unit

Global Price Benchmark for Febuxostat across major pharmaceutical markets
Market	Price (USD/unit)	Currency	Reference
United States	$X.XX	USD	According to the FDA's Orange Book, Febuxostat is approved for use in the United States.
United Kingdom	$X.XX	GBP	As per the NHS Drug Tariff, Febuxostat is listed for reimbursement.
Germany	$X.XX	EUR	The European Medicines Agency (EMA) has authorized Febuxostat for use in Germany.
Australia	$X.XX	AUD

Supply Chain Risk Assessment — Febuxostat

API sourcing, concentration risk, storage requirements, and current alerts

HIGH RISK

1API Sourcing & Raw Material Dependency

India's pharmaceutical industry, including the production of Febuxostat, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) sourced from China. According to the U.S. Pharmacopeia, 41% of KSMs used in U.S.-approved APIs are solely sourced from China, highlighting a significant dependency. This reliance poses a substantial risk, as any disruption in the supply chain from China can directly impact the availability and production of Febuxostat in India.

Recent geopolitical tensions have exacerbated these vulnerabilities. In February 2026, military conflicts in the Middle East led to the closure of the Strait of Hormuz, a critical maritime chokepoint through which a significant portion of global oil and gas supplies transit. This disruption has had cascading effects on global supply chains, including the pharmaceutical sector, by increasing transportation costs and causing delays. Such events underscore the fragility of the supply chain for essential raw materials and the need for diversification to mitigate risks.

2Supplier Concentration & Single-Source Risk

The export market for Febuxostat from India is notably concentrated, with the top five exporters accounting for 73.0% of the total export value. Ajanta Pharma Limited alone holds a 34.4% share, amounting to $16.8 million USD. This high level of supplier concentration introduces a single-source risk; any operational or regulatory issues affecting these key exporters could significantly disrupt the supply chain.

Access Complete Febuxostat Trade Intelligence

Shipment-level records, verified supplier contacts, buyer histories, and pricing analytics for all 3,494 transactions across 91 markets.

Request Demo View Pricing

Frequently Asked Questions — Febuxostat Exports from India

Data-backed answers sourced from Indian Customs shipping bill records

Who are the top febuxostat exporters from India?

The leading febuxostat exporters from India are AJANTA PHARMA LIMITED, MSN LABORATORIES PRIVATE LIMITED, ALEMBIC PHARMACEUTICALS LIMITED, and 12 others. AJANTA PHARMA LIMITED leads with 34.4% market share ($16.8M). The top 5 suppliers together control 73.0% of total export value.

What is the total export value of febuxostat from India?

The total export value of febuxostat from India is $48.9M, recorded across 3,494 shipments from 182 active exporters to 91 countries. The average shipment value is $14.0K.

Which countries import febuxostat from India?

India exports febuxostat to 91 countries. The top importing countries are PHILIPPINES (52.3%), UNITED STATES (23.7%), CANADA (4.8%), HUNGARY (2.7%), UNITED KINGDOM (2.5%), which together account for 86.1% of total export value.

What is the HS code for febuxostat exports from India?

The primary HS code for febuxostat exports from India is 30049099. This 8-digit classification falls under Chapter 30 (pharmaceutical products) of the Harmonized System and is used by Indian Customs (DGFT) to track and report pharmaceutical export flows.

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Febuxostat

Febuxostat

Top Febuxostat Exporters from India

Top Countries Importing Febuxostat from India

Who Supplies Febuxostat to India?

Quick Facts

Related Lipid & Metabolism

Related Analysis

Need Details?

Febuxostat — Export Intelligence Video

Regulatory Landscape — Febuxostat

1FDA & US Market Regulatory Status

2EU & UK Regulatory Framework

3WHO Essential Medicines & Global Standards

4India Regulatory Classification

5Patent & Exclusivity Status

6Recent Industry Developments

Global Price Benchmark — Febuxostat

Supply Chain Risk Assessment — Febuxostat

1API Sourcing & Raw Material Dependency

2Supplier Concentration & Single-Source Risk

Access Complete Febuxostat Trade Intelligence

Frequently Asked Questions — Febuxostat Exports from India

Who are the top febuxostat exporters from India?

What is the total export value of febuxostat from India?

Which countries import febuxostat from India?

What is the HS code for febuxostat exports from India?

Official References & Regulatory Resources

Research Methodology & Data Transparency

Suresh Sormare

Primary Data Source

India Cost Advantage

3Geopolitical & Shipping Disruptions

4Risk Mitigation Recommendations

What is the average price of febuxostat exports from India?

Which ports handle febuxostat exports from India?

Why is India a leading exporter of febuxostat?

What certifications do Indian febuxostat exporters need?

How many buyers import febuxostat from India?

What is the market share of the top febuxostat exporter from India?

Analysis Methodology